Kidney transplant patients: which drug keeps you healthier?
NCT ID NCT06044493
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested two similar immunosuppressant drugs, MYREPTIC-N® and MY-REPT®, in 158 adults who had a kidney transplant at least a year ago. The goal was to see how well each drug prevented organ rejection, graft loss, or death. Participants continued their usual anti-rejection medicines during the trial. The results help doctors choose the best option for long-term transplant care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Seoul National University Hospital
Seoul, 03080, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could the choice of anesthesia quiet the Body's surgical stress response?
- A simple blood test could spot kidney transplant rejection early
- Can your gut bacteria change how transplant drugs work?
- Blood test may take the guesswork out of transplant drug dosing
- Immunotherapy may treat skin cancer in kidney transplant patients without rejection
- Could a daily pill shield transplant patients from a common virus?